Breccia M, Iurlo A, Pane F, Scortechini AR, Rossi AR, Santoro M, Cerrano M, Lunghi F, Maggi A, Di Renzo N, Sargentini V, Piciocchi A, Tringali C, Malato A. Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy. haematol [Internet]. 2020Sep.10 [cited 2026May14];. Available from: https://haematologica.org/article/view/14178